Clinical Trials - Listings

New Image

Clinical trials play an essential role in bringing new treatments to all patients. Our patients who have participated in clinical trials enjoy the reassurance and security they get from close monitoring and are proud to play a part in advancing medicine.

The following clinical trials are being offered through Urologic Consultants of Southeastern Pennsylvania and/or Philadelphia Cancer Treatment Radiation Oncology Center. For more information about these or any other clinical trials, visit our site on CenterWatch and talk with your doctor. 

Prostate Cancer 

Clinical trial NCT01946204 (ARN-509-003)

This study will evaluate whether a drug to treat prostate cancer is effective in men whose cancer has not spread but who have a rising PSA. 

Clinical trial NCT02200614 (Bayer 17712)

This study will assess the effectiveness of a drug in men with prostate cancer that has not spread but who have a rising PSA.

Clinical trial NCT02531516 (PCR3003)

This study will determine the effectiveness of a drug plus hormone therapy in men with prostate cancer who are undergoing radiation therapy and are at high risk for metastases.

Clinical trial NCT02319837 (MDV3100-13)

This study will assess the effectiveness of a drug combination in men with prostate cancer who have undergone radical prostatectomy and/or radiation therapy as primary treatment and now have a rising PSA and are at high risk for metastases. 

Clinical trial NCT01981109 (Predict P12-1)

This is an observational study of men with prostate cancer that has not spread but who have a rising PSA and are at high risk for metastases. 

Clinical trial NCT02380274 (Astellas ONC-MA-1004)

This is an observational study of treatment of men with castration-resistant prostate cancer and a rising PSA.

Clinical trial NCT02799745 (Astellas 9785-MA-1010)

This study will compare the rate of prostate cancer progression between patients treated with enzalutamide and patients undergoing active surveillance.

Clinical trial NCT02531516 (PCR3003) 

This study will determine the effectiveness of a drug plus hormone therapy in men with prostate cancer who are undergoing radiation therapy and are at high risk for metastases.

Clinical trial NCT02319837 (MDV3100-13)

This study will assess the effectiveness of a drug combination in men with prostate cancer who have undergone radical prostatectomy and/or radiation therapy as prima-ry treatment and now have a rising PSA and are at high risk for metastases. 

Clinical trial NCT02663908 (Ferring 000108)

This trial will test two drugs used to treat advanced prostate cancer to see how well they reduce the risk of cardiovascular complications in patients with prostate cancer and cardiovascular disease.

Clinical trial NCT02799602 (Bayer 1777)

This study will assess the effectivenes of a drug in combination with hormone therapy and chemotherapy in patients with metastatic hormone-sensitive prostate cancer.

Metastatic Prostate Cancer

Clinical trial NCT02111577 (Sotio SP005)

This study will evaluate the effectiveness of a drug added to standard chemotherapy for men with castration-resistant prostate cancer that has spread and who have a rising PSA.

Clinical trial NCT02043678 (Bayer 15396)

This study will evaluate the effectiveness of adding radium-223 dichloride to standard treatment for men with prostate cancer that has spread to the bone.

Clinical trial NCT02489318(PCR3002)

This study will evaluate the effectiveness of adding a drug to hormone therapy in men with hormone-sensitive prostate cancer that has spread. 

Clinical trial NCT02380274 (Astellas ONC-MA-1004)

This is an observational study of treatment of men with castration-resistant prostate cancer and a rising PSA.

Bladder Cancer

Clinical trial NCT02449239 (VB4-845-02-IIIA)

This study will evaluate the effectiveness of a biological as an alternative to cystectomy in men and women with bladder cancer previously treated with bacillus Calmette-Guérin (BCG).

Clinical trial NCT02563561(SPI-EOQ-13-305)

This study will evaluate the effectiveness of a drug placed into the bladder after surgery to remove bladder tumors.

Clinical trial NCT02449239 (VB4-845-02-IIIA)

This study will evaluate the effectiveness of a biological as an alternative to cystecto-my in men and women with bladder cancer previously treated with bacillus Calmette-Guérin (BCG).

Overactive Bladder

Clinical trial NCT01945489 (GMA-OAB-113-BOTOX)

This is a study to evaluate onabotulinumtoxinA (BOTOX®) for treatment of urinary incontinence in men and women with overactive bladder (OAB) not properly managed with an anticholinergic

Clinical trial NCT (GTx-G20012)

This study will determine whether a medication is safe and effective in the treatment of stress urinary incontinence in postmenopausal women.

Nephropathy

Clinical trial NCT02118714 (M12-919)

This study is being conducted to evaluate the effects of atrasentan on sperm production and the function of the testicles in men with Type 1 or 2 diabetes and nephropathy.

Benign Prostatic Hyperplasia

Clinical trial NCT02757768 (178-MA-1008)

This is a study to evaluate the effectiveness of a drug to treat overactive bladder (OAB) symptoms due to Benign Prostatic Hyperplasia (BPH).